Clinical Trials Logo

Clinical Trial Summary

Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam as an adjunctive therapy for depression. The main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.


Clinical Trial Description

Pragmatic, randomised, controlled, parallel-group, pilot trial. Trial participants will be patients admitted to St Patrick's University Hospital for treatment of a depressive episode. The investigators aim to recruit up to 20 participants who will be eligible for this study and randomly allocate 10 patients to each group. The participants will undergo usual inpatient care as prescribed by their treating team for the index acute depressive episode. Both participants and assessors will be blind to treatment allocation. Consented participants will be randomly allocated in a 1:1 ratio to a four week course of either once-weekly ketamine or midazolam infusions. Block randomisation will be independently performed. Physical, psychotomimetic and cognitive outcomes will be monitored before, during and after infusions. Blood samples will be taken at four time-points in the first infusion session and before the final infusion for neuroplasticity biomarker studies. Both groups will continue treatment as usual. Participates will also be followed up over a three month period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03256162
Study type Interventional
Source St Patrick's Hospital, Ireland
Contact
Status Completed
Phase Phase 1
Start date September 7, 2017
Completion date September 21, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03396744 - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression Phase 1/Phase 2
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Completed NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Terminated NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Recruiting NCT04998773 - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression N/A
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Completed NCT03658824 - Behavioural Activation for Bipolar Depression: A Case Series N/A
Suspended NCT03674671 - Ketamine Versus Electroconvulsive Therapy in Depression Phase 3
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Recruiting NCT05296356 - OSU6162 in Bipolar Depression (OBID) Phase 2
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1
Completed NCT00566150 - Levetiracetam in the Management of Bipolar Depression N/A